200 related articles for article (PubMed ID: 38338684)
1. Prognostic Markers in Tyrosine Kinases Specific to Basal-like 2 Subtype of Triple-Negative Breast Cancer.
Limsakul P; Choochuen P; Jungrungrueang T; Charupanit K
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338684
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers.
Limsakul P; Choochuen P; Charupanit G; Charupanit K
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672350
[TBL] [Abstract][Full Text] [Related]
3. Molecular stratification within triple-negative breast cancer subtypes.
Wang DY; Jiang Z; Ben-David Y; Woodgett JR; Zacksenhaus E
Sci Rep; 2019 Dec; 9(1):19107. PubMed ID: 31836816
[TBL] [Abstract][Full Text] [Related]
4. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
Masuda H; Baggerly KA; Wang Y; Zhang Y; Gonzalez-Angulo AM; Meric-Bernstam F; Valero V; Lehmann BD; Pietenpol JA; Hortobagyi GN; Symmans WF; Ueno NT
Clin Cancer Res; 2013 Oct; 19(19):5533-40. PubMed ID: 23948975
[TBL] [Abstract][Full Text] [Related]
5. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
6. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
7. Alpha-crystallin B chains enhance cell migration in basal-like 2 triple-negative breast cancer cells.
Yang L; Higashisaka K; Haga Y; Tsujino H; Nagano K; Tsutsumi Y
Pharmazie; 2022 Feb; 77(2):45-47. PubMed ID: 35209962
[TBL] [Abstract][Full Text] [Related]
8. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
Hill DP; Harper A; Malcolm J; McAndrews MS; Mockus SM; Patterson SE; Reynolds T; Baker EJ; Bult CJ; Chesler EJ; Blake JA
BMC Cancer; 2019 Nov; 19(1):1039. PubMed ID: 31684899
[TBL] [Abstract][Full Text] [Related]
10. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
11. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
[TBL] [Abstract][Full Text] [Related]
12. Targeting triple-negative breast cancer: A clinical perspective.
Popovic LS; Matovina-Brko G; Popovic M; Punie K; Cvetanovic A; Lambertini M
Oncol Res; 2023; 31(3):221-238. PubMed ID: 37305385
[TBL] [Abstract][Full Text] [Related]
13. Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles.
Akhouayri L; Ostano P; Mello-Grand M; Gregnanin I; Crivelli F; Laurora S; Liscia D; Leone F; Santoro A; Mulè A; Guarino D; Maggiore C; Carlino A; Magno S; Scatolini M; Di Leone A; Masetti R; Chiorino G
Hum Genomics; 2022 Dec; 16(1):70. PubMed ID: 36536459
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
Tseng LM; Chiu JH; Liu CY; Tsai YF; Wang YL; Yang CW; Shyr YM
Breast Cancer Res Treat; 2017 Jun; 163(2):241-254. PubMed ID: 28299476
[TBL] [Abstract][Full Text] [Related]
15. Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes
Olsson M; Larsson P; Johansson J; Sah VR; Parris TZ
Front Cell Dev Biol; 2023; 11():1237673. PubMed ID: 37771376
[No Abstract] [Full Text] [Related]
16. Molecular Subtyping of Triple Negative Breast Cancer by Surrogate Immunohistochemistry Markers.
Kumar S; Bal A; Das A; Bhattacharyya S; Laroiya I; Khare S; Singh G
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):251-257. PubMed ID: 33337632
[TBL] [Abstract][Full Text] [Related]
17. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.
Ring BZ; Hout DR; Morris SW; Lawrence K; Schweitzer BL; Bailey DB; Lehmann BD; Pietenpol JA; Seitz RS
BMC Cancer; 2016 Feb; 16():143. PubMed ID: 26908167
[TBL] [Abstract][Full Text] [Related]
18. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer: A run-through of features, classification and current therapies.
Manjunath M; Choudhary B
Oncol Lett; 2021 Jul; 22(1):512. PubMed ID: 33986872
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]